CTRI/2015/01/005409已完成4 期
A Multicentric open label non-interventional post marketing Surveillance study to evaluate safety and tolerability of BEâ??s inactivated vero cell derived Japanese Encephalitis vaccine in â?¥1 to â?¤3 year old healthy children in a two dose schedule. - None
Biological ELimited0 个研究点目标入组 800 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Subjects of either sex who are between >=1 to <=3 years at the time of 1st vaccination
- •2.Written informed consent obtained prior to screening from subjectâ??s Parents/Guardian or the legally acceptable representative (LAR)
- •3.Free of clinically significant health problems as established by medical history and physical examination before entering into the study
- •4.Ability of the subjectâ??s Parents/Guardian or the legally acceptable representative (LAR) to understand and comply with the requirements of the protocol
排除标准
- •1.Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine.
- •2.Any family history of Immunodeficiency or autoimmune disease.
- •3.Administration of chronic (defined as more than 14 days) immune-suppressants or other immune-modifying drugs within 6 months of vaccination. (For corticosteroids, this meant prednisone, or equivalent, >=0.05 mg/kg/day. Topical and inhaled steroids allowed).
- •4.History of severe hypersensitivity reactions (in particular to a component of the investigational vaccine, anaphylaxis or severe cases of atopy requiring emergency treatment or hospital admission).
- •5.Any confirmed or suspected Infection with HIV, HCV and Hepatitis B (HBsAg).
- •6.Subjects with history of severe cardiopulmonary, hepatobiliary / renal disorders and or malignancy.
- •7.Any acute infection within two weeks prior to enrolment.
- •8.Inability or unwillingness by the subjectâ??s parent/guardian or legally acceptable representative(s) to provide informed consent and to abide by the requirements of the study.
- •9.Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion.
研究者
相似试验
已完成
4 期
observational study in patients with hypertensioCTRI/2018/03/012787Dr Reddys Laboratories Ltd500
已完成
4 期
observational study in patients with blood pressureCTRI/2018/02/011727Dr Reddys Laboratories Ltd600
尚未招募
4 期
Post marketing study to evaluate the Safety and Efficacy of Wikoryl Drops in infants (1 year)CTRI/2021/12/039024Alembic Pharmaceuticals Limited
已完成
4 期
Active post marketing surveillance (PMS) to evaluate the safety and efficacy of Sinarest Oral Drops in infants of common cold or allergic rhinitis.CTRI/2021/11/037913Centaur Pharmaceuticals Pvt Ltd415
已完成
4 期
Active post marketing surveillance to evaluate the safety and efficacy of Sinarest Syrup in children of common cold or allergic rhinitis.CTRI/2021/11/037912Centaur Pharmaceuticals Pvt Ltd417
